FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo
MEXICO CITY (Reuters) - Mexico will not necessarily follow the U.S. Food and Drug Administration (FDA) in approving Gilead Science Inc's antiviral drug remdesivir for use in COVID-19 patients, a top Mexican health official said on Friday.
Mexico's health regulator Cofepris has already twice denied approval for the drug with a "non-favorable" opinion, deputy health minister Hugo Lopez-Gatell told his regular nightly news conference.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
